Denali Therapeutics Inc. Balance Sheet
DNLI / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 10 fiscal years. All figures from audited SEC 10-K filings.
Denali Therapeutics Inc. had $1.1B in total assets and $1.0B in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $205.3M | $175.0M | $127.1M | $218.0M | $293.5M | $507.1M | $77.1M | $218.4M | $218.4M | $39.9M |
| Current Assets | $900.7M | $864.4M | $1.1B | $1.4B | $897.2M | $1.5B | $430.0M | $480.8M | $409.6M | - |
| PP&E (Net) | $52.4M | $55.2M | $45.6M | $44.1M | $38.9M | $40.8M | $46.7M | $25.2M | $14.9M | - |
| Total Assets | $1.1B | $1.4B | $1.2B | $1.5B | $1.4B | $1.6B | $553.2M | $662.0M | $486.7M | - |
| Current Liabilities | $98.4M | $102.2M | $78.0M | $363.9M | $378.2M | $71.7M | $45.3M | $32.8M | $14.2M | - |
| Shareholders' Equity | $1.0B | $1.2B | $1.0B | $1.2B | $394.9M | $546.8M | $465.8M | -$94.2M | $465.8M | -$94.2M |